



Effects of the viability of *Lactobacillus rhamnosus* GG on rotavirus infection in neonatal rats

Hanna Ventola, Liisa Lehtoranta, Mari Madetoja, Marja-Leena Simonen-Tikka, Leena Maunula, Merja Roivainen, Riitta Korpela, Reetta Holma

Hanna Ventola, Liisa Lehtoranta, Riitta Korpela, Reetta Holma, Institute of Biomedicine, Pharmacology, University of Helsinki, FI-00014 Helsinki, Finland

Mari Madetoja, Toxis Ltd Oy, Lemminkäisenkatu 14-18 C, FI-20520 Turku, Finland

Marja-Leena Simonen-Tikka, Merja Roivainen, Intestinal Viruses Unit, National Institute for Health and Welfare, FI-00271 Helsinki, Finland

Leena Maunula, Department of Food Hygiene and Environmental Health, University of Helsinki, FI-00014 Helsinki, Finland

Author contributions: Holma R, Korpela R, and Madetoja M designed the study; Holma R supervised and organized the study; Ventola H and Lehtoranta L designed and carried out the animal experiments, subsequent molecular analyses, and drafted the manuscript; Madetoja M designed and carried out the animal experiments; Simonen-Tikka ML participated in the rotavirus-PCR analysis; Maunula L cultivated and provided the rotavirus strain, and participated in drafting the manuscript; Roivainen M participated in the study design, and helped to develop the rotavirus-PCR method; all authors read and approved the final manuscript. Supported by Valio Ltd and the Finnish Funding Agency of Technology and Innovation; The Foundation for Nutrition Research has financially contributed to Liisa Lehtoranta's doctoral studies

Correspondence to: Dr. Reetta Holma, Institute of Biomedicine, Pharmacology, University of Helsinki, PO Box 63, FI-00014 Helsinki, Finland. reetta.holma@helsinki.fi

Telephone: +358-9-19124366 Fax: +358-9-19125364

Received: January 13, 2011 Revised: February 28, 2012

Accepted: March 20, 2012

Published online: November 7, 2012

Abstract

AIM: To study the effects of live and dead *Lactobacillus rhamnosus* GG (GG) on rotavirus infection in a neonatal rat model.

METHODS: At the age of 2 d, suckling Lewis rat pups were supplemented with either live or dead GG and the treatment was continued daily throughout the experi-

ment. At the age of 5 and 6 d the pups received oral rotavirus (RV) SA-11 strain. The pups were sacrificed at the age of 7 or 8 d by decapitation. The gastrointestinal tract was removed and macroscopic observations were done. The consistency of feces in the colon was classified using a four-tier system. RV was detected from the plasma, small intestine, colon and feces by real-time quantitative polymerase chain reaction (PCR).

RESULTS: In this neonatal rat model, RV induced a mild-to-moderate diarrhea in all except one pup of the RV-inoculated rats. RV moderately reduced body weight development from day 6 onwards. On day 7, after 2 d of RV infection, live and dead GG groups gained significantly more weight than the RV group without probiotics [36% ($P = 0.001$) and 28% ($P = 0.031$), respectively]. In addition, when compared with the RV control group, both live and dead GG reduced the weight ratio of colon/animal body weight to the same level as in the healthy control group, with reductions of 22% ($P = 0.002$) and 28% ($P < 0.001$), respectively. Diarrhea increased moderately in both GG groups. However, the diarrhea incidence and severity in the GG groups were not statistically significantly different as compared with the RV control group. Moreover, observed diarrhea did not provoke weight loss or death. The RV control group had the largest amount of RV PCR-positive samples among the RV-infected groups, and the live GG group had the smallest amount. Rats receiving live GG had significantly less RV in the colon ($P = 0.027$) when compared with the RV control group. Live GG was also more effective over dead GG in reducing the quantity of RV from plasma ($P = 0.047$).

CONCLUSION: Both live and dead GG have beneficial effects in RV infection. GG may increase RV clearance from the body and reduce colon swelling.

© 2012 Baishideng. All rights reserved.

Key words: Diarrhea; *Lactobacillus rhamnosus* GG; Neonatal rat; Rotavirus; Viability

Peer reviewers: Marco Silano, Department of Human Nutrition and Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy; Gopal Nath, Professor, Microbiology, Institute of Medical Sciences, BHU, Varanasi 221005, India

Ventola H, Lehtoranta L, Madetoja M, Simonen-Tikka ML, Maunula L, Roivainen M, Korpela R, Holma R. Effects of the viability of *Lactobacillus rhamnosus* GG on rotavirus infection in neonatal rats. *World J Gastroenterol* 2012; 18(41): 5925-5931 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v18/i41/5925.htm> DOI: <http://dx.doi.org/10.3748/wjg.v18.i41.5925>

INTRODUCTION

Group A rotaviruses are the leading cause of acute gastroenteritis in children < 2 years of age and account annually for nearly 600 000 child deaths worldwide^[1]. Rotavirus-induced diarrhea causes severe dehydration and vomiting which can be fatal for malnourished babies. In developed countries rotavirus gastroenteritis causes a large economic burden with a substantial number of hospitalizations, doctor visits, and medical costs. Two vaccines are available to prevent RV infection, but their use may be limited by financial constraints especially in low-income countries.

The use of probiotic bacteria has gained considerable attention as a safe and accessible form of treatment for gastrointestinal diseases^[2,3]. *Lactobacillus rhamnosus* GG (GG), in particular, has been effective in reducing both duration^[3-6], and severity^[6,7] of rotavirus-induced diarrhea. The therapeutic capacity of GG against rotavirus gastroenteritis might be due to its ability to adhere to intestinal epithelial cells and compete for binding with the pathogens^[8,9], or displace bound pathogens^[10], stabilize and reinforce the mucosal barrier^[11-13], and stimulate the local antigen specific and nonspecific immune responses^[5,12,14]. However, the effect mechanisms of GG in rotavirus diarrhea are not completely understood.

Only a few studies have addressed the effects of inactivated probiotics in rotavirus diarrhea^[5,15]. When studying the effects of inactivated and live GG on acute RV diarrhea in children, both product forms equally promoted clinical recovery from diarrhea, but only live GG enhanced an IgA antibody response to RV^[5]. In mice, in contrast to live GG, heat-killed GG failed to protect animals from duration or severity of RV diarrhea^[15]. However, these studies did not include an untreated control group to allow comparison between the effects of product forms and RV.

In order to gain more understanding of the effect mechanisms of live and dead GG in RV-induced diarrhea, we compared their effects in the suckling rat RV SA-11 infection model with regard to parameters of infection severity such as weight gain, colon weight, con-

sistency of the feces, and also measured the amount of rotavirus in plasma, intestine, and feces.

MATERIALS AND METHODS

Animals

This study was approved by the Animal Care and Use Committee of the State Provincial Office of Southern Finland (license number ESAVI-2010-06221_Ym-23). Pregnant-specific pathogen-free Lewis rats were obtained from Harlan (Horst, The Netherlands) and they were allowed to give birth naturally in the test facility. The birth time of the pups was monitored twice a day. All pups were born on the same day within 12 h. Prior to all experiments, each litter was adjusted to 6 pups per dam to avoid biological variation due to litter size. The litters were randomly assigned to 4 experimental groups (4 dams with 6 pups each, $n = 24$): rats infected with RV SA-11 alone (RV control group); dead GG treated + RV SA-11 infected rats (dead GG group); live GG treated + RV SA-11 infected rats (live GG group); and minimum essential medium (MEM) control animals (healthy control group). The rat pups remained with their dams throughout the study. Control and inoculated groups were housed in the same individually ventilated Scantainer (Scanburg, Denmark), and each RV-infected group in its own Scantainer, in a normal rat cage (Makrolon III) with Aspen chips bedding (Tapvei Oy, Kaavi, Finland) and nest material (Aspen chips PM90L/R). The temperature was 22 ± 2 °C with relative humidity 50%-95%. Lighting was artificial, 12 h light and 12 h dark (18:00-06:00). Food (TEKLAD T.2916 IRR*; Irradiated Global 16%, Rodent Diet for mice and rats, Harlan) and deionized water were autoclaved and provided *ad libitum* from the day of the rats arrival until the completion of the experiments. The animals were identified individually by dorsal numbering.

Lactobacillus rhamnosus GG products

Viability was determined by plating the GG preparation after inactivation and no colony forming units (cfu) were detected. Both live and dead GG (ATCC 53103) were obtained from Valio (Valio Ltd, Helsinki, Finland). Prior use live GG stock (10^{11} cfu/mL) was aliquoted in de Man, Rogosa and Sharpe culture medium broth and stored at -20 °C. Powdered dead GG (killed at Valio Ltd, trade secret) at an equivalent cfu number of 10^{11} cfu/g of viable GG was maintained at room temperature. For the experiments live GG was thawed and dead GG weighed, and both were prepared daily in PBS at a concentration of 3×10^9 cfu/mL.

Virus propagation

Simian RV SA-11 strain was grown in a continuous cell line of rhesus monkey kidney cells, MA-104. The cells were cultivated in MEM containing 10% heat-inactivated fetal bovine serum supplemented with 2 mmol L-glutamine, penicillin and streptomycin in roller flasks in roller apparatus at 37 °C. When the cells had a

confluency of 70%-80%, they were inoculated from a stock containing 10^8 pfu/mL of plaque-purified rotaviruses. Before inoculation, RV stock was treated with 10-20 $\mu\text{g/mL}$ (final concentration) of trypsin (Sigma, St Louis, United States) for 30 min at 37 °C. RV stock in dilution 10^{-4} was added to each roller bottle. After incubation for 1 h, 30 mL of serum-free MEM with 1 $\mu\text{g/mL}$ of trypsin was added, and the cultivation was continued for 48 h at 37 °C. RV were harvested by freeze-thawing of cells for 3 times, cell debris was removed by low-speed centrifugation, supernatant was collected, divided into aliquots, and stored at -70 °C until use. RV titre was determined as 1.4×10^8 pfu/mL.

Animal experiments

The pups were weighed at fixed times daily before, and twice a day after, RV infection. At the age of 2 d, pups received a single daily 0.05 mL dose of either dead or live GG supplementation (1.5×10^8 cfu/pup). RV SA-11 was inoculated by plastic feeding tube in 3 separate doses to achieve the total amount of 10^8 pfu/pup as follows: at the age of 5 d pups received 2 RV doses (0.3 mL each), and the third dose at the age of 6 d (0.12 mL) in order to boost the RV infection. MEM containing 100 \times glutamine, penicillin 100 IU/mL, streptomycin 100 $\mu\text{g/mL}$ was used as a healthy control. After inoculations pups were returned to their dams and allowed to suckle.

Clinical indices and specimen collection

The pups were randomized to be exsanguinated from either 2 d or 3 d post-infection at the age of 7 d and 8 d. The blood samples were collected from all animals by decapitation into EDTA tubes (Venosafe™), and the plasma was obtained by centrifugation (10 min, 4000 rpm), and frozen at -20 °C within 1 h from sampling. The gastrointestinal tract was removed for macroscopic observations and specimen collection immediately after blood sampling. Small intestine was collected and weighed; colon tissue was collected and removed from its content by gently pushing along the tissue length by a spatula after which it was weighed. The feces were collected by carefully emptying the colon and rectum. Specimens were stored in dried ice until storing them at -80 °C. Consistency of feces was classified from 0-3 using a four-tier system: [0 = normal feces, 1 = slight diarrhea (feces is pale but solid); 2 = moderate diarrhea (feces is pale and semi-solid); 3 = strong diarrhea (feces is clearly wet)].

Sample processing

Plasma samples were thawed and viral RNA was extracted from 0.1 mL of sample with BioSprint® 96 One-For-All Vet-kit (Qiagen GmbH, Hilden, Germany), using the automated KingFisher mL purification system (Thermo Fisher Scientific, Vantaa, Finland) according to the manufacturer's instructions.

Frozen small intestine, colon, and feces were homogenized for nucleic acid extraction. Feces were processed on ice in 0.2 mL of 10% protease-inhibitor solution containing 1% bovine serum albumin, 10 mmol pefabloc

(Roche Applied Science, Mannheim, Germany), 100 $\mu\text{g/mL}$ aprotinin (Sigma-Aldrich, St. Louis, MO, United States) 100 $\mu\text{g/mL}$ leupeptin (Sigma-Aldrich) in Eagle minimum essential medium I (Gibco, Carlsbad, CA) supplemented with 5% fetal calf serum, and 20 mmol Hepes (pH 7.4). Suspensions were vortexed with sterile glass beads, centrifuged (10 min, 5000 rpm), and viral RNA was extracted from supernatants with E.Z.N.A.® Total RNA Kit (Omega Bio-Tek, Doraville, GA, United States) according to manufacturer's instructions.

Colon and the entire small intestine with its contents were homogenized with sterile glass rods, and 30 mg of homogenized tissue was added into 0.6 mL of RLT buffer (Qiagen) and incubated at 37 °C for 10 min in a water bath. The lysate was centrifuged with QIAshredder (Qiagen) (2 min, 12 000 $\times g$), and RNA was extracted with RNeasy Mini Kit (Qiagen) or BioSprint® 96 One-For-All Vet-kit (Qiagen) using the automated KingFisher mL purification system as above.

Detection of rotavirus

A total of 10 μL of the viral RNA was reverse transcribed into cDNA with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, United States) in a 20 μL reaction volume according to the manufacturer's instructions. real-time (RT) reaction was performed as described with few modifications^[16]. Depending on the sample material, RNA was first denatured for 5 min at 95 °C, and RT was performed by incubating the reaction mixture for 10 min at 25 °C, 120 min at 37 °C, and 5 min at 85 °C. The quantitative polymerase chain reaction (qPCR) protocol and the primers which target the VP7 gene of RV were designed according to the primers described by Li *et al*^[17]. Briefly, the qPCR reaction was carried out in 25 μL reaction mixtures consisting of 12.5 μL of 2 \times SYBR Premix Ex Taq™ (Takara, Dalian, China), 0.5 μL of each primer (20 $\mu\text{mol/L}$ final concentrations), 0.5 μL ROX Ref Dye II (50 \times), 4 μL of RV cDNA template, and 7 μL of sterile water (Sigma-Aldrich). The thermocycling profile included initial denaturation at 95 °C for 30 s, followed by 45 cycles of 95 °C for 5 s, 58 °C for 20 s, and 72 °C for 30 s. Finally, the melting curve analysis was performed at 95 °C for 1 min, 55 °C for 30 s, and 95 °C for 30 s. RNA isolated from cultured RV SA-11 samples was used as a positive control to establish the standard curve, and sterile water (Sigma-Aldrich) as a negative control. The samples were regarded RV SA-11 positive if the melting peak temperature was 83 ± 1.5 °C. The results were analyzed by comparing the cycle threshold (CT) values, which were inversely correlated with the amount of RV VP7 gene in the sample, i.e., the lower the CT value, the greater the amount of gene in sample.

Statistical analysis

Analysis of variance was applied to compare the groups with respect to weight gain and colon weight, and the results are given as means with standard error of the mean \pm SE. In cases of significant global *P*-values,




Figure 1 Percentage weight gain of the rats. The rat pups were weighed 1-2 times daily after day 2 during the experiment. On days 5 and 6, rotavirus (RV) was inoculated orally to the rats. Weight gain is expressed as percentual weight gain from the beginning of the experiment. ^a*P* < 0.05 vs RV control group; ^c*P* < 0.05 vs dead GG group.




Figure 2 Weight of colon without feces. Results between groups are presented as the weight ratio of colon/animal. *P* = 0.002, *P* = 0.001, *P* < 0.001 vs rotavirus (RV) control.

multiple comparisons were performed and the *P*-values were Bonferroni corrected. RV diarrhea occurrence and severity between the study groups were analyzed using logistic regression analysis. Statistical differences in the *CT*-values between RV-infected groups were analyzed using Kruskal-Wallis test (global test) and Mann-Whitney *U*-test (pair-wise comparisons). *P*-values < 0.05 were considered statistically significant. The data were analyzed using PASW version 18.0 (SPSS Inc. Chicago, IL, United States).

RESULTS

Clinical investigations

Weight gain: The pups were weighed 1-2 times daily

Healthy control group (n = 5)	RV control group (n = 6)	Dead GG group (n = 6)	Live GG group (n = 6)
0	0	2	3
0	1	2	2
0	2	2	2
0	1	3	3
0	2	2	3
NA ¹	1	1	1

There was no statistically significant difference between groups. ¹Animal deceased during the experiment due to technical error in dosing. RV: Rotavirus; NA: Not analyzed.

Group	RV PCR-positive samples			
	Plasma	Small intestine	Colon	Feces
Healthy control group	0/5	0/5	0/5	0/5
RV control group	6/6	5/6	6/6	5/6
Dead GG group	6/6	4/6	6/6	4/6
Live GG group	6/6	2/6	6/6	3/6

Samples with cycle threshold (*CT*)-values < 45 were regarded as positive. RV: Rotavirus; PCR: Polymerase chain reaction.

during the experiment. There were no significant differences in body weight development before the virus inoculation between the study groups. RV moderately reduced body weight development from day 6 onwards (1 d after the infection) when compared with the pups receiving only MEM (Figure 1). RV did not severely compromise the condition of the pups. One pup died from the healthy group due to technical difficulties in dosing. The groups pre-colonized with live or dead GG had gained significantly more weight on day 7 than the RV group without probiotics [36% (*P* = 0.001) and 28% (*P* = 0.031), respectively].

Colon weight: Tissue samples were blindly collected and weighed at necropsy. In the large intestine, RV increased the weight of colon. Results between groups were compared by measuring the ratio of colon weight/body weight (Figure 2). When compared with the RV control group, both live and dead GG reduced the weight ratio of the colon to the same level as seen in the healthy control group, with reductions of 22% (*P* = 0.002) and 28% (*P* < 0.001), respectively.

Diarrhea: At the necropsy, diarrhea was determined in a blinded fashion by scoring the consistency of feces using the four-tier system from 0-3. RV induced a mild-to-moderate diarrhea in all except one of the RV-inoculated rats when compared with the healthy control group. In live and dead GG groups, diarrhea seemed to be moderately increased. However, the diarrhea incidence or severity in the groups was not statistically significant (*P* > 0.05) as compared with the RV control group (Table 1).




Figure 3 Rotavirus detection in plasma, small intestine, colon, and feces by real-time quantitative polymerase chain reaction. Limit of detection of the reaction was cycle threshold (CT) 45. The lines represent the mean of the CT-values. $P = 0.047$ vs RV control group, $P = 0.027$ vs dead GG group.

Rotavirus detection

The number of RV PCR-positive samples in the study groups is shown in Table 2. In the healthy control group, RV was detected from none of the samples. Overall, the RV control group had the largest amount of RV PCR-positive samples among the 3 groups, and live GG group the smallest amount. By comparing the CT values between the groups, we found that rats receiving live GG had significantly less RV VP7 gene in the colon ($P = 0.027$) when compared with the RV control group (Figure 3). Live GG was also more effective than dead GG in reducing the quantity of RV from plasma ($P = 0.047$).

DISCUSSION

In the present study conducted in a neonatal rat model, we characterized the effects of live and dead probiotic strain *Lactobacillus rhamnosus* GG on RV-induced diarrhea. We found that both groups receiving GG had smaller amounts of RV in the intestinal tissues and feces over the RV control group. In particular, live GG was effective in reducing the number of RV in the colon. Similar studies exist in mice, where live GG supplementation in

combination with antibodies reduced rhesus RV load in the small intestine^[15]. This increased RV clearance could be one of the effect mechanisms of GG in RV diarrhea, as it could shorten the duration of disease, as seen in clinical studies^[5,18,19]. Since RV is also capable of spreading systemically, and infecting extraintestinal tissues such as liver, kidney, and central nervous system^[20-23], the other potentially beneficial effect mechanism of GG against RV diarrhea might be its ability to inhibit the virus entering the blood circulation. Here, live GG appeared to reduce the quantity of RV in plasma.

Similar to other studies, RV SA-11 was effective in inducing diarrhea in the rat pups^[24,25]. Interestingly, we found that both live and dead GG seemed to slightly, though not significantly, increase diarrhea. *Lactobacillus* species in general seem to have an anti-diarrheal effect in clinical and *in vivo* studies^[5,6,26,27]. Especially in neonatal rats, *Lactobacillus casei* (*L. casei*) DN-114 001 strain in fermented milk decreased clinical signs of RV SA-11-induced diarrhea, reduced the number of RV antigens from the small intestine 48 h after infection, and reduced RV antigen load in the feces^[24]. Our results may be explained by the fact that nitric oxide (NO), which may

stimulate the enteric nervous system and induce water secretion into a luminal space further causing diarrhea^[28], is released by RV-infected enterocytes^[29], and GG also induces NO in macrophages^[30]. Enhanced diarrhea in the GG groups may further lead to the increased clearance of RV from the intestinal tissues by inhibiting adherence of RV, and “flushing” the virus from the body. However, we did not include a group receiving only GG, and cannot confirm whether the amount of GG could have an effect on the consistency of feces. On the other hand, another study did not report any changes in the feces in groups receiving probiotic supplements alone^[24].

Although the pups suffered from diarrhea, both groups receiving either live or dead GG gained more weight than the RV control group after RV inoculation. However, another probiotic strain, *L. casei* DN-114 001, failed to induce weight gain in a similar RV SA-11 rat model^[24], suggesting that the effect is strain specific. Interestingly, after day 6, the percentage weight gain was also reduced in the uninfected healthy control group. It is possible that a relatively large number of dosings during a short period of time partly inhibited rat pups to suckle milk from their dams.

RV induces inflammation and promotes tissue swelling by activating cytokine response of intestinal epithelial cells^[31]. RV-induced tissue swelling could this way increase weight of the colon. Interestingly, we found that both live and dead GG reduced colon weight. In the GG group this reduction may result from the GG's ability to stimulate the production of anti-inflammatory cytokines^[32]. These results further support the idea that GG might shorten the duration, and enhance the recovery from RV diarrhea.

The question of whether unviable and killed bacteria could have similar beneficial effects as live probiotic strains is contradicted. In clinical studies, heat-inactivated GG in children was unable to elicit local or systemic effects in rotavirus diarrhea^[5]. In addition, a heat-inactivated probiotic mixture including GG was ineffective against antibiotic-associated diarrhea when compared to equivalent live strains^[33]. In children with milk allergy, heat-inactivated GG treatment was associated with diarrhea^[34]. However, animal experiments conducted with unviable GG showed that the unviable form has beneficial effects against several inflammatory conditions such as arthritis and *Escherichia coli* lipopolysaccharide-induced inflammation in the lungs and liver of rats^[32,35]. This finding was possibly seen in our study as reduced colon weight. Nevertheless, live GG seemed to be more effective over dead GG in increasing the weight gain of rat pups after RV infection, and was more efficient in reducing the number of RV from plasma. The effects of dead bacteria, however, might depend on the method of inactivation. For instance, inactivation by heat or irradiation might disrupt the surface protein conformation of the bacteria, inhibiting the probiotic's ability to adhere to epithelial cell^[36]. In case the anti-diarrheal effects are due to secreted bioactive or antimicrobial peptides^[13,36,37], GG

needs to be viable.

In conclusion, only live GG decreased the number of RV in the colon of infected rat pups. However, dead GG had also some potential to alleviate RV infection possibly by reducing tissue swelling. The results provide new insights into aspects of the bacterial strain's viability, offering new possibilities to develop novel functional food matrices.

COMMENTS

Background

Group A rotaviruses are responsible for most cases of gastroenteritis in children under 2 years of age worldwide. Probiotics have gained an important role as adjuvant therapy in the treatment of acute diarrhea. Probiotic strain *Lactobacillus rhamnosus* GG (GG) in particular is known to reduce the duration of rotavirus-induced diarrhea in young children. However, it is unknown whether the viability of the strain plays a critical role in the probiotic's beneficial effects on diarrhea.

Research frontiers

The potential of unviable/inactivated/killed bacteria to relieve rotavirus (RV) gastroenteritis is not known. In this preliminary study, the authors explored the effects of both live and dead GG in RV infection in a neonatal rat model.

Innovations and breakthroughs

Recent clinical and animal studies have shown that GG relieves RV infection by shortening the duration of diarrhea, and reduces the amount of RV in intestinal tissues. In the present study the authors found only live GG reduced the amount of RV in intestinal tissues. However, the dead product form was found to have a potential to decrease RV diarrhea-induced weight reduction, and inhibit RV-induced colon swelling.

Applications

The results of this study indicate that the viable and dead forms of the bacterium have different favorable effects on RV infection. Dead product forms would have a great potential in the food industry by providing new product applications, increasing product shelf life, and reducing storage costs.

Terminology

Probiotic bacteria are defined as live microorganisms that have beneficial effects on human health. However, data regarding whether dead bacteria could have similar favorable health effects to live probiotic strains is limited.

Peer review

This study has investigated in experimental animals the effects of probiotics on rotavirus-induced diarrhea using *Lactobacillus* strain. They have used killed and live *Lactobacillus* strain in animals in which diarrhea was induced by rotaviruses. The findings are supportive of early observations of similar nature and are of clinical significance.

REFERENCES

- 1 Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. *Emerg Infect Dis* 2003; **9**: 565-572
- 2 Bibiloni R, Simon MA, Albright C, Sartor B, Tannock GW. Analysis of the large bowel microbiota of colitic mice using PCR/DGGE. *Lett Appl Microbiol* 2005; **41**: 45-51
- 3 Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human *Lactobacillus* strain (*Lactobacillus casei* sp strain GG) promotes recovery from acute diarrhea in children. *Pediatrics* 1991; **88**: 90-97
- 4 Grandy G, Medina M, Soria R, Terán CG, Araya M. Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children. *BMC Infect Dis* 2010; **10**: 253
- 5 Kaila M, Isolauri E, Saxelin M, Arvilommi H, Vesikari T. Viable versus inactivated *Lactobacillus* strain GG in acute rota-

- virus diarrhoea. *Arch Dis Child* 1995; **72**: 51-53
- 6 **Van Niel CW**, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. *Pediatrics* 2002; **109**: 678-684
 - 7 **Canani RB**, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, De Vincenzo A, Albano F, Passariello A, De Marco G, Manguso F, Guarino A. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. *BMJ* 2007; **335**: 340
 - 8 **Elo S**, Saxelin M, Salminen S. Attachment of *Lactobacillus casei* strain GG to human colon carcinoma cell line Caco-2: comparison with other dairy strains. *Lett Appl Microbiol* 1991; **13**: 154-156
 - 9 **Kankainen M**, Paulin L, Tynkkynen S, von Ossowski I, Reunanen J, Partanen P, Satokari R, Vesterlund S, Hendrickx AP, Lebeer S, De Keersmaecker SC, Vanderleyden J, Hämäläinen T, Laukkanen S, Salovuori N, Ritari J, Alatalo E, Korpela R, Mattila-Sandholm T, Lassig A, Hatakka K, Kinnunen KT, Karjalainen H, Saxelin M, Laakso K, Surakka A, Palva A, Salusjärvi T, Auvinen P, de Vos WM. Comparative genomic analysis of *Lactobacillus rhamnosus* GG reveals pili containing a human- mucus binding protein. *Proc Natl Acad Sci USA* 2009; **106**: 17193-17198
 - 10 **Lee YK**, Puong KY, Ouwehand AC, Salminen S. Displacement of bacterial pathogens from mucus and Caco-2 cell surface by lactobacilli. *J Med Microbiol* 2003; **52**: 925-930
 - 11 **Maragkoudakis PA**, Chingwaru W, Gradisnik L, Tsakalidou E, Cencic A. Lactic acid bacteria efficiently protect human and animal intestinal epithelial and immune cells from enteric virus infection. *Int J Food Microbiol* 2010; **141** Suppl 1: S91-S97
 - 12 **Schiffirin EJ**, Blum S. Interactions between the microbiota and the intestinal mucosa. *Eur J Clin Nutr* 2002; **56** Suppl 3: S60-S64
 - 13 **Yan F**, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. *Gastroenterology* 2007; **132**: 562-575
 - 14 **Zhang L**, Xu YQ, Liu HY, Lai T, Ma JL, Wang JF, Zhu YH. Evaluation of *Lactobacillus rhamnosus* GG using an *Escherichia coli* K88 model of piglet diarrhoea: Effects on diarrhoea incidence, faecal microflora and immune responses. *Vet Microbiol* 2010; **141**: 142-148
 - 15 **Pant N**, Marcotte H, Brüßow H, Svensson L, Hammarström L. Effective prophylaxis against rotavirus diarrhoea using a combination of *Lactobacillus rhamnosus* GG and antibodies. *BMC Microbiol* 2007; **7**: 86
 - 16 **Gutiérrez-Aguirre I**, Steyer A, Boben J, Gruden K, Poljsak-Prijatelj M, Ravnikar M. Sensitive detection of multiple rotavirus genotypes with a single reverse transcription-real-time quantitative PCR assay. *J Clin Microbiol* 2008; **46**: 2547-2554
 - 17 **Li D**, Gu AZ, Yang W, He M, Hu XH, Shi HC. An integrated cell culture and reverse transcription quantitative PCR assay for detection of infectious rotaviruses in environmental waters. *J Microbiol Methods* 2010; **82**: 59-63
 - 18 **Guarino A**, Canani RB, Spagnuolo MI, Albano F, Di Benedetto L. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhoea. *J Pediatr Gastroenterol Nutr* 1997; **25**: 516-519
 - 19 **Majamaa H**, Isolauri E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. *J Pediatr Gastroenterol Nutr* 1995; **20**: 333-338
 - 20 **Crawford SE**, Patel DG, Cheng E, Berkova Z, Hyser JM, Ciarlet M, Finegold MJ, Conner ME, Estes MK. Rotavirus viremia and extraintestinal viral infection in the neonatal rat model. *J Virol* 2006; **80**: 4820-4832
 - 21 **de Villiers FP**, Steele AD, Driessen M. Central nervous system involvement in neonatal rotavirus infection. *Ann Trop Paediatr* 2003; **23**: 309-312
 - 22 **Mossel EC**, Ramig RF. Rotavirus genome segment 7 (NSP3) is a determinant of extraintestinal spread in the neonatal mouse. *J Virol* 2002; **76**: 6502-6509
 - 23 **Ray P**, Fenaux M, Sharma S, Malik J, Subodh S, Bhatnagar S, Greenberg H, Glass RI, Gentsch J, Bhan MK. Quantitative evaluation of rotaviral antigenemia in children with acute rotaviral diarrhoea. *J Infect Dis* 2006; **194**: 588-593
 - 24 **Guérin-Danan C**, Meslin JC, Chambard A, Charpilienne A, Relano P, Bouley C, Cohen J, Andrieux C. Food supplementation with milk fermented by *Lactobacillus casei* DN-114 001 protects suckling rats from rotavirus-associated diarrhoea. *J Nutr* 2001; **131**: 111-117
 - 25 **Pérez-Cano FJ**, Castell M, Castellote C, Franch A. Characterization of clinical and immune response in a rotavirus diarrhoea model in suckling Lewis rats. *Pediatr Res* 2007; **62**: 658-663
 - 26 **Guandalini S**, Pensabene L, Zikri MA, Dias JA, Casali LG, Hoekstra H, Kolacek S, Massar K, Micetic-Turk D, Papadopoulou A, de Sousa JS, Sandhu B, Szajewska H, Weizman Z. *Lactobacillus* GG administered in oral rehydration solution to children with acute diarrhoea: a multicenter European trial. *J Pediatr Gastroenterol Nutr* 2000; **30**: 54-60
 - 27 **Szajewska H**, Skórka A, Rusczyński M, Gieruszczak-Białek D. Meta-analysis: *Lactobacillus* GG for treating acute diarrhoea in children. *Aliment Pharmacol Ther* 2007; **25**: 871-881
 - 28 **Izzo AA**, Mascolo N, Capasso F. Nitric oxide as a modulator of intestinal water and electrolyte transport. *Dig Dis Sci* 1998; **43**: 1605-1620
 - 29 **Rodríguez-Díaz J**, Banasaz M, Istrate C, Buesa J, Lundgren O, Espinoza F, Sundqvist T, Rottenberg M, Svensson L. Role of nitric oxide during rotavirus infection. *J Med Virol* 2006; **78**: 979-985
 - 30 **Korhonen R**, Korpela R, Saxelin M, Mäki M, Kankaanranta H, Moilanen E. Induction of nitric oxide synthesis by probiotic *Lactobacillus rhamnosus* GG in J774 macrophages and human T84 intestinal epithelial cells. *Inflammation* 2001; **25**: 223-232
 - 31 **Rollo EE**, Kumar KP, Reich NC, Cohen J, Angel J, Greenberg HB, Sheth R, Anderson J, Oh B, Hempson SJ, Mackow ER, Shaw RD. The epithelial cell response to rotavirus infection. *J Immunol* 1999; **163**: 4442-4452
 - 32 **Li N**, Russell WM, Douglas-escobar M, Hauser N, Lopez M, Neu J. Live and heat-killed *Lactobacillus rhamnosus* GG: effects on proinflammatory and anti-inflammatory cytokines/chemokines in gastrostomy-fed infant rats. *Pediatr Res* 2009; **66**: 203-207
 - 33 **Wenus C**, Goll R, Loken EB, Biong AS, Halvorsen DS, Florholmen J. Prevention of antibiotic-associated diarrhoea by a fermented probiotic milk drink. *Eur J Clin Nutr* 2008; **62**: 299-301
 - 34 **Kirjavainen PV**, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. *J Pediatr Gastroenterol Nutr* 2003; **36**: 223-227
 - 35 **Baharav E**, Mor F, Halpern M, Weinberger A. *Lactobacillus* GG bacteria ameliorate arthritis in Lewis rats. *J Nutr* 2004; **134**: 1964-1969
 - 36 **Ouwehand AC**, Tölkö S, Kulmala J, Salminen S, Salminen E. Adhesion of inactivated probiotic strains to intestinal mucus. *Lett Appl Microbiol* 2000; **31**: 82-86
 - 37 **Lu R**, Fasano S, Madayiputhiya N, Morin NP, Nataro J, Fasano A. Isolation, identification, and characterization of small bioactive peptides from *Lactobacillus* GG conditional media that exert both anti-Gram-negative and Gram-positive bactericidal activity. *J Pediatr Gastroenterol Nutr* 2009; **49**: 23-30

S- Editor Gou SX L- Editor Logan S E- Editor Zhang DN